The prevention of pregnancy‐related venous thromboembolism

• Published in: British journal of haematology 2015-01, Vol.168 (2), p.163-174
• Main Authors: Guimicheva, Boriana, Czuprynska, Julia, Arya, Roopen
• Format: Article
• Language: English
• Subjects: Anticoagulants - therapeutic use; Female; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Pregnancy; Pregnancy Complications, Cardiovascular - prevention & control; Pregnancy Complications, Cardiovascular - therapy; pregnancy‐related venous thromboembolism; Risk Factors; venous thromboembolism; Venous Thromboembolism - prevention & control; Venous Thromboembolism - therapy
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.13159

Summary Pregnancy‐related venous thromboembolism (VTE) remains one of the leading causes of maternal mortality and morbidity in the developed world. There is a lack of high‐level data surrounding the use of thromboprophylaxis in pregnancy. In the UK, following the publication of the first Royal College of Obstetricians and Gynaecologists (RCOG) guideline for VTE prophylaxis during pregnancy and the puerperium in 2004, a fall in maternal deaths secondary to VTE was observed during the subsequent triennium (2006–2008). For the first time since 1985, VTE was no longer the most common cause of maternal death. Low‐molecular‐weight‐heparin (LMWH) is generally the agent of choice for thromboprophylaxis in this setting, and is considered safe and efficacious. The accurate risk stratification of women in order to allow the targeted provision of thromboprophylaxis is challenging. A number of international guidelines support risk assessment for pregnancy‐related VTE and the provision of LMWH for those who are deemed at sufficiently high risk. This review describes the importance of VTE in pregnancy and the puerperium, the part played by different risk factors and the role of thromboprophylaxis in this group of patients.